The order carried out as a part of the projects titled:
IBD: „PRE-CLINICAL AND CLINICAL RESEARCH OF CANDIDATE FOR INNOVATIVE DRUG IN ASTHMA AND INFLAMMATORY BOWEL DISEASES THERAPY” (POIR.01.01.01 00-0168/15)
IPF: DEVELOPMENT OF A FIRST-IN-CLASS SMALL MOLECULE DRUG CANDIDATE FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS THROUGH CHITOTRIOSIDASE INHIBITION (POIR.01.01.01-00-0551/15)
co-financed by the National and European Union Funds and because of the competitiveness principle.
We hereby look for Contractor ready to perform the service:
Professional consulting and advice on in vivo efficacy studies of new compounds developed by OncoArendi using in vivo models of inflammatory bowel disease, asthma, chronic obstructive pulmonary diseases, idiopathic pulmonary fibrosis